NASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $65.75 +0.40 (+0.61%) Closing price 10/12/2026 04:00 PM EasternExtended Trading$65.90 +0.16 (+0.24%) As of 09:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BridgeBio Pharma Stock (NASDAQ:BBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BridgeBio Pharma alerts:Sign Up Key Stats Today's Range$65.20▼$66.4250-Day Range$65.04▼$84.6752-Week Range$52.75▼$93.42Volume1.78 million shsAverage Volume3.14 million shsMarket Capitalization$12.85 billionP/E RatioN/ADividend YieldN/APrice Target$105.42Consensus RatingModerate Buy Company Overview BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease. BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions. The company’s acoramidis, marketed in the United States as Attruby, was approved by the U.S. Food and Drug Administration in 2024 for the treatment of adults with cardiomyopathy caused by transthyretin-mediated amyloidosis. Founded in 2015, BridgeBio is headquartered in Palo Alto, California, and conducts research, clinical development and commercial activities through its subsidiaries and collaborations in the United States and international markets. The company was co-founded and is led by Neil Kumar, who serves as chief executive officer. Its products and investigational therapies are developed for patients with serious conditions that often have limited or no approved treatment options.AI Generated. May Contain Errors. Read More BridgeBio Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreBBIO MarketRank™: BridgeBio Pharma scored higher than 79% of companies evaluated by MarketBeat, and ranked 124th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 21 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBridgeBio Pharma has a consensus price target of $105.42, representing about 60.3% upside from its current price of $65.75.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($2.66) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -18.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -18.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.73% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 5.85.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 8.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.47 News SentimentBridgeBio Pharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for BridgeBio Pharma this week, compared to 10 articles on an average week.Search Interest6 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows10 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,578,119.00 in company stock.Percentage Held by Insiders14.23% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBIO Stock News HeadlinesBridgeBio Highlights Attruby Data Showing Lower Hospitalization Risk In ATTR-CM At HFSA 2026October 12 at 6:29 AM | rttnews.comBridgeBio Pharma Has Lost 28% Since July: Barclays Sees 139% UpsideOctober 12 at 6:29 AM | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 13 at 1:00 AM | Investors Alley (Ad)BridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic HypoparathyroidismOctober 12 at 6:29 AM | rttnews.comBridgeBio's Encaleret Shows Symptoms, Bone Turnover Improvements in Phase 3 Trial in ADH1October 12 at 6:29 AM | finance.yahoo.comAcoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health RecordsOctober 11 at 5:00 PM | globenewswire.comBridgeBio reports improved symptoms in Phase 3 trial of rare-disease drugOctober 11 at 12:46 PM | seekingalpha.comBridgeBio Pharma (NASDAQ:BBIO) CEO Sells $690,800.00 in StockSeptember 22, 2026 | insidertrades.comSee More Headlines BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $76.49 at the start of the year. Since then, BBIO shares have decreased by 14.0% and is now trading at $65.75. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.20. The business's revenue for the quarter was up 120.4% on a year-over-year basis. Read the conference call transcript. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $308 million in an IPO on Thursday, June 27th 2019. The company issued 20,500,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's top institutional investors include GAMMA Investing LLC and Farther Finance Advisors LLC. Insiders that own company stock include Global Investors Lp Viking, Genetic Disorder LP Kkr, Charles J Homcy, Frank Mccormick, Neil Kumar, Thomas Trimarchi, Maricel Apuli, Brian C Stephenson, Andrew Lo, Andrea Ellis, Ronald J Daniels, Randal W Scott, Hannah Valantine and Jennifer E Cook. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/10/2026Today10/13/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, BBIO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BBIO CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees839Year Founded2014Price Target and Rating Average Price Target for BridgeBio Pharma$105.42 High Price Target$156.00 Low Price Target$81.00 Potential Upside/Downside+60.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$724.93 million Net Margins-97.03% Pretax Margin-98.68% Return on EquityN/A Return on Assets-61.19% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.17 Sales & Book Value Annual Sales$502.08 million Price / Sales25.60 Cash FlowN/A Price / Cash FlowN/A Book Value($10.77) per share Price / Book-6.10Miscellaneous Outstanding Shares195,490,000Free Float167,669,000Market Cap$12.85 billion OptionableOptionable Beta0.97 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BBIO) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
